Pharma Focus Asia

Thermo Fisher Scientific Plans to Expand New Facility in Singapore

Introduction:

Thermo Fisher Scientific Inc, plans to invest US$130 million to expand a new facility in Singapore. The expanded sterile filling capacity will be dedicated for developing Therapies and Vaccines.

Features:

This expansion broadens the capacity for the development and manufacturing of therapies and vaccines particularly in the Asia Pacific region.

The project consists of developing two new sterile filling lines in Singapore. The first-ever high-speed sterile line approved for live virus filling and the second additional line for standard fill/finish.

The new sterile filling capacity consists of cleanroom capacity, labs and warehousing facilities to increase production. It is expected that up to 30 million sterile doses per month would be produced once the facility begins.

It is expected that the new Sterile Filling Capacity is supposed to start its operation in 2022 and add additional jobs for 300 people.

Specifications:

NameThermo Fisher Scientific
TypeExpansion
BudgetUS$130 million
Year2022
magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference